Skip to main content

Research Repository

Advanced Search

All Outputs (63)

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia (2022)
Journal Article
Taynton, T., Barlow, G., & Allsup, D. (2022). PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia. JAC-Antimicrobial Resistance, 4(4), Article dlac074. https://doi.org/10.1093/jacamr/dlac074

Mould-active antifungal prophylaxis is frequently used to prevent invasive fungal infection in patients with acute leukaemia being treated with intensive chemotherapy. Invasive fungal infections are difficult to diagnose, and despite the use of proph... Read More about PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia.

A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol (2022)
Journal Article
Northgraves, M., Allsup, D., Cohen, J., Huang, C., Turgoose, J., & Ali, S. (2022). A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol. PLoS ONE, 17(2), Article e0263195. https://doi.org/10.1371/journal.pone.0263195

Background Acute leukaemias (AL) are aggressive but potentially curable blood cancers that can potentially affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking... Read More about A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol.

Long‐term follow‐up of 415 patients with chronic lymphocytic leukaemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials, a comprehensive assessment of prognostic factors (2022)
Journal Article
Allsup, D. J., Craig, Z., Cairns, D., Howard, D., Hockaday, A., Bloor, A., …Hillmen, P. (in press). Long‐term follow‐up of 415 patients with chronic lymphocytic leukaemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials, a comprehensive assessment of prognostic factors. American Journal of Hematology, https://doi.org/10.1002/ajh.26483

Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia (2021)
Journal Article
Naylor-Adamson, L., Chacko, A., Booth, Z., Caserta, S., Jarvis, J., Khan, S., …Arman, M. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Frontiers in immunology, 12, Article 766272. https://doi.org/10.3389/fimmu.2021.766272

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec)... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia.

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study (2021)
Journal Article
Chatzikonstantinou, T., Kapetanakis, A., Scarfò, L., Karakatsoulis, G., Allsup, D., Cabrero, A. A., …Ghia, P. (in press). COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01450-8

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-d... Read More about COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Hungate, E., Sunter, N. J., Elstob, C., Xu, Y., …Allan, J. M. (2021). Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature communications, 12(1), Article 6233. https://doi.org/10.1038/s41467-021-26551-x

Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 104... Read More about Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies (2021)
Journal Article
Pepper, A. G., Zucchetto, A., Norris, K., Tissino, E., Polesel, J., Soe, Z., …Pepper, C. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, https://doi.org/10.1038/s41375-021-01322-1

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia (2021)
Journal Article
Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, chemo-free, therap... Read More about Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., …Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature communications, 12(1), Article 665. https://doi.org/10.1038/s41467-020-20822-9

© 2021, The Author(s). Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognost... Read More about Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020)
Journal Article
Cooper, N., Abbs, S., Farmery, J. H., Deevi, S. V., Thaventhiran, J. E., Adhya, Z., …Smith, K. G. C. (2020). Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 583(7814), 90-95. https://doi.org/10.1038/s41586-020-2265-1

Primary immunodeficiency (PID) is characterized by recurrent and often life-threatening infections, autoimmunity and cancer, and it poses major diagnostic and therapeutic challenges. Although the most severe forms of PID are identified in early child... Read More about Whole-genome sequencing of a sporadic primary immunodeficiency cohort.

Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints (2020)
Journal Article
Chester, R., Das, A. A. K., Medlock, J., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2020). Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints. ACS Applied Bio Materials, 3(2), 789-800. https://doi.org/10.1021/acsabm.9b00770

We report a cell recognition chromatography approach for blood cancer cell separation from healthy peripheral blood mononuclear cells (PBMCs) based on sizematched functionalized particle imprints. Negative imprints were prepared from layers of 15 μm... Read More about Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints.

Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints (2019)
Journal Article
Das, A. A., Remaud, P., Medlock, J., Das, A. A. K., Allsup, D. J., Madden, L. A., …Paunov, V. N. (2019). Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints. Materials Chemistry Frontiers, 4(1), 197-205. https://doi.org/10.1039/c9qm00531e

We report a new approach for separation of blood cancer cells from healthy white blood cells based on cell recognition by surface functionalised particle imprints. We prepared polymeric particle imprints from a layer of suspension of monodisperse PMM... Read More about Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints.

Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants (2019)
Journal Article
Bury, L., Megy, K., Stephens, J. C., Grassi, L., Greene, D., Gleadall, N., …Westbury, S. K. (2020). Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Human Mutation, 41(1), 277-290. https://doi.org/10.1002/humu.23927

Human Mutation published by Wiley Periodicals, Inc. The heterogeneous manifestations of MYH9-related disorder (MYH9-RD), characterized by macrothrombocytopenia, Döhle-like inclusion bodies in leukocytes, bleeding of variable severity with, in some ca... Read More about Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants.

Germline selection shapes human mitochondrial DNA diversity (2019)
Journal Article
Wei, W., Tuna, S., Keogh, M. J., Smith, K. R., Aitman, T. J., Beales, P. L., …Chinnery, P. F. (2019). Germline selection shapes human mitochondrial DNA diversity. Science, 364(6442), Article eaau6520. https://doi.org/10.1126/science.aau6520

INTRODUCTION Only 2.4% of the 16.5-kb mitochondrial DNA (mtDNA) genome shows homoplasmic variation at >1% frequency in humans. Migration patterns have contributed to geographic differences in the frequency of common genetic variants, but population... Read More about Germline selection shapes human mitochondrial DNA diversity.

Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood (2019)
Journal Article
Das, A. A., Medlock, J., Liang, H., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2019). Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood. Journal of Materials Chemistry B, 7(22), 3497-3504. https://doi.org/10.1039/c9tb00679f

We report a large scale preparation of bioimprints of layers of cultured human leukemic HL60 cells which can perform cell shape and size recognition from a mixture with peripheral blood mononuclear cells (PBMCs). We demonstrate that the bioimprint-ce... Read More about Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood.